[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.108.121. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,076
Citations 0
Letters to the Editor
May 2013

Methylphenidate vs Atomoxetine: Personalized Medicine in Attention- Deficit/Hyperactivity Disorder

Author Affiliations

Author Affiliations: Department of Child and Adolescent Mental Health, University Hospital of Erlangen, Erlangen (Drs Heinrich, Studer, Moll, and Kratz), and Heckscher-Klinikum, Munich (Dr Heinrich), Germany.

JAMA Psychiatry. 2013;70(5):545. doi:10.1001/jamapsychiatry.2013.760

In the light of personalized medicine, future studies should not only address the question of whether one therapy is generally superior than another but also investigate which therapy may work best in a particular patient. In this respect, the article by Schulz and colleagues,1 in which the neural mechanisms of methylphenidate and atomoxetine during response inhibition were studied in children with attention-deficit/hyperactivity disorder (ADHD) by functional magnetic resonance imaging, appears to be highly relevant, particularly since neural changes are considered in relation to clinical improvements.

First Page Preview View Large
First page PDF preview
First page PDF preview
×